Deutsche Bank
VIR icon

Deutsche Bank’s Vir Biotechnology VIR Stock Holding History

Deutsche Bank’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Buy
134,258
+43,525
+48% +$414K ﹤0.01% 2139
2026
Q1 		$813K Sell
90,733
-115,489
-56% -$920K ﹤0.01% 2298
2025
Q4 		$1.24M Buy
206,222
+3,118
+2% +$18.6K ﹤0.01% 2081
2025
Q3 		$1.16M Buy
203,104
+7,609
+4% +$38.9K ﹤0.01% 2078
2025
Q2 		$985K Sell
195,495
-12,795
-6% -$68.6K ﹤0.01% 2097
2025
Q1 		$1.35M Sell
208,290
-8,444
-4% -$75.1K ﹤0.01% 1993
2024
Q4 		$1.59M Buy
216,734
+27,515
+15% +$217K ﹤0.01% 1986
2024
Q3 		$1.42M Buy
189,219
+143,182
+311% +$1.24M ﹤0.01% 1957
2024
Q2 		$410K Buy
46,037
+4,572
+11% +$43.8K ﹤0.01% 2426
2024
Q1 		$420K Buy
41,465
+4
+0% +$41 ﹤0.01% 2435
2023
Q4 		$417K Sell
41,461
-1,015
-2% -$9.28K ﹤0.01% 2460
2023
Q3 		$398K Buy
42,476
+5,219
+14% +$74.4K ﹤0.01% 2314
2023
Q2 		$914K Sell
37,257
-76,950
-67% -$1.93M ﹤0.01% 2047
2023
Q1 		$2.66M Sell
114,207
-28,880
-20% -$739K ﹤0.01% 1521
2022
Q4 		$3.62M Buy
143,087
+103,692
+263% +$2.54M ﹤0.01% 1354
2022
Q3 		$759K Sell
39,395
-3,845
-9% -$97.7K ﹤0.01% 2142
2022
Q2 		$1.1M Sell
43,240
-1,238
-3% -$28.9K ﹤0.01% 2116
2022
Q1 		$1.14M Sell
44,478
-3,748
-8% -$111K ﹤0.01% 2262
2021
Q4 		$2.02M Sell
48,226
-1,676
-3% -$65.7K ﹤0.01% 1980
2021
Q3 		$2.17M Buy
49,902
+2,762
+6% +$120K ﹤0.01% 2035
2021
Q2 		$2.23M Buy
47,140
+5,310
+13% +$241K ﹤0.01% 2125
2021
Q1 		$2.15M Sell
41,830
-3,898
-9% -$210K ﹤0.01% 2122
2020
Q4 		$1.23M Buy
45,728
+14,925
+48% +$485K ﹤0.01% 2312
2020
Q3 		$1.06M Buy
30,803
+7,410
+32% +$319K ﹤0.01% 2160
2020
Q2 		$958K Buy
23,393
+20,902
+839% +$702K ﹤0.01% 2254
2020
Q1 		$86K Sell
2,491
-320
-11% -$8.6K ﹤0.01% 3315
2019
Q4 		$34K Buy
+2,811
New +$37.7K ﹤0.01% 4111

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Deutsche Bank's VIR Position: Q2 2026 in Review

Deutsche Bank increased its Vir Biotechnology (VIR) stake by 48% in Q2 2026, buying an estimated $414K and bringing the position to 134,258 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #2139.

Deutsche Bank first reported a position in VIR in Q4 2019 and has held it in 27 quarters since. The position peaked at $3.62M in Q4 2022. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Deutsche Bank held 134,258 shares of Vir Biotechnology worth $1.37M as of Q2 2026.
  • Deutsche Bank bought 43,525 Vir Biotechnology shares in Q2 2026, an estimated $414K.
  • Vir Biotechnology made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #2139 holding.
  • Deutsche Bank first reported a position in Vir Biotechnology in Q4 2019 and has held it in 27 quarters since.
  • Deutsche Bank's Vir Biotechnology position peaked at $3.62M in Q4 2022.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.